SCHEMBL6355769

SCHEMBL6355769

O=C(Cc1cc(Cl)ccc1Cl)Nc1cccc(Cl)c1Cl

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.62
KMT2A Q03164 7/20 0.62
KCNJ5 P48544 1/20 0.55
KCNJ3 P48549 1/20 0.55
POLB P06746 1/20 0.50
GALR3 O60755 1/20 0.47
NR2F2 P24468 1/20 0.47
KCNQ2 O43526 1/20 0.46
LMNA P02545 3/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 2/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
MAPK1 P28482 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6355103 0.85 MEN1 (0.74) MEN1KMT2AKCNJ5KCNJ3KCNQ2
SCHEMBL6360899 0.82 PTGER1 (0.54) MEN1KMT2AALDH1A1MAPT
SCHEMBL2008072 0.78 MEN1 (1.00) MEN1KMT2APOLBLMNAKDM4E
SCHEMBL4002979 0.75 MEN1 (0.79) MEN1KMT2ALMNAKDM4EALDH1A1
SCHEMBL7736629 0.74 MEN1 (0.70) MEN1KMT2AKCNJ5KCNJ3POLB
SCHEMBL9621530 0.73 MEN1 (0.83) MEN1KMT2APOLBLMNAKDM4E
SCHEMBL28833417 0.73 MEN1 (0.77) MEN1KMT2ALMNAKDM4EALDH1A1
SCHEMBL4010958 0.73 MEN1 (0.77) MEN1KMT2APOLBLMNAKDM4E
SCHEMBL6356182 0.73 MEN1 (0.52) MEN1KMT2ALMNAKDM4EALDH1A1
SCHEMBL10144069 0.72 KMT2A (0.64) MEN1KMT2AKCNQ2LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 MEN1 3860/4885KMT2A 1711/4885KCNJ5 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.